The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

NCT05263570 · clinicaltrials.gov ↗
RECRUITING
Status
200
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Shengjing Hospital